Eli Lilly is continuing its investment in manufacturing by allocating an additional $3 billion to enhance production capabilities. The pharmaceutical company aims to ramp up the manufacturing of its blockbuster drugs and future products.
One of the key initiatives includes expanding a factory in Kenosha County, Wisconsin, which was acquired earlier this year. This expansion will cater to the increasing demand for injectable products such as Mounjaro and Zepbound, which collectively generated $4.4 billion in sales for Lilly in the third quarter of this year.
